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Abstract:
Rituximab plus polychemotherapy is standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED
trial compares obinutuzumab to rituximab. GAINED (NCT01659099) is an open-label, randomized phase 3
trial. Transplant-eligible patients (18-60yrs) with untreated aged-adjusted international prognostic
index (aaIPI) ≥1 DLBCL were randomized (1:1) between obinutuzumab or rituximab. Patients were stratified
by aaIPI (1; 2-3) and chemotherapy regimen (ACVBP; CHOP). Consolidation treatment was determined
according to response assessed by centrally reviewed interim semi-quantitative PET. Responders after
cycle 2 and 4 (PET2-/PET4-) received planned immuno-chemotherapy consolidation. Responders only after
cycle 4 (PET2+/4-) received high-dose methotrexate plus transplantation. The primary objective was an 8%
improvement (HR=0.73; 80% power; alpha risk 2.5%; one-sided) in 2-year event-free survival (EFS) in the
obinutuzumab arm. Events included death, progression, PET 2 or 4 positivity, modification of planned
treatment. From September 20, 2012, 670 patients were enrolled (obinutuzumab n=336; rituximab n=334).
383 (57.2%) were aaIPI 2-3, 339 (50.6%) received CHOP and 324 (48.4%) received ACVBP. Median follow-up
was 38.7 months. The 2-year EFS were similar in obinutuzumab and rituximab groups (59.8% vs 56.6%;
p=0.123; HR=0.88). The 2-year PFS in the whole cohort was 83.1% (95%CI 80–85.8). PET2-/4- and PET2+/4-
had similar 2-year PFS and OS (89.9% vs 83.9%) and 94.8% vs 92.8%). The 2-year PFS and OS for PET4+
patients were 62% and 83.1%. Grade 3-5 infections were more frequent in the obinutuzumab arm (21% vs
12%). Obinutuzumab is not superior to rituximab in untreated aaIPI≥1 DLBCL transplant-eligible patients.
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Key points 
Obinutuzumab does not provide any significant additional tumor control in newly diagnosed transplant-eligible 
DLBCL compared to rituximab 
 
Interim PET staging enables accurate monitoring and could be considered for use in routine practive of patients 
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ABSTRACT  
Rituximab plus polychemotherapy is standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED trial 
compares obinutuzumab to rituximab. GAINED (NCT01659099) is an open-label, randomized phase 3 trial. 
Transplant-eligible patients (18-60yrs) with untreated aged-adjusted international prognostic index (aaIPI) ≥1 
DLBCL were randomized (1:1) between obinutuzumab or rituximab. Patients were stratified by aaIPI (1; 2-3) 
and chemotherapy regimen (ACVBP; CHOP). Consolidation treatment was determined according to response 
assessed by centrally reviewed interim semi-quantitative PET. Responders after cycle 2 and 4 (PET2-/PET4-) 
received planned immuno-chemotherapy consolidation. Responders only after cycle 4 (PET2+/4-) received high-
dose methotrexate plus transplantation. The primary objective was an 8% improvement (HR=0.73; 80% power; 
alpha risk 2.5%; one-sided) in 2-year event-free survival (EFS) in the obinutuzumab arm. Events included death, 
progression, PET 2 or 4 positivity, modification of planned treatment.  From September 20, 2012, 670 patients 
were enrolled (obinutuzumab n=336; rituximab n=334). 383 (57.2%) were aaIPI 2-3, 339 (50.6%) received 
CHOP and 324 (48.4%) received ACVBP. Median follow-up was 38.7 months. The 2-year EFS were similar in 
obinutuzumab and rituximab groups (59.8% vs 56.6%; p=0.123; HR=0.88). The 2-year PFS in the whole cohort 
was 83.1% (95%CI 80–85.8). PET2-/4- and PET2+/4- had similar 2-year PFS and OS (89.9% vs 83.9%) and 
94.8% vs 92.8%). The 2-year PFS and OS for PET4+ patients were 62% and 83.1%. Grade 3-5 infections were 
more frequent in the obinutuzumab arm (21% vs 12%). Obinutuzumab is not superior to rituximab in untreated 
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Polychemotherapy regimen (such as CHOP or ACVBP) plus Rituximab is a standard of care in diffuse large B-
cell lymphoma (DLBCL)
1–5
. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody 
designed to enhance the antibody-dependent cell mediated cytotoxicity as compared to Rituximab. Indeed, the 
addition of Obinutuzumab to induction chemotherapy may provide a better disease control compared to 
rituximab plus chemotherapy in previously untreated DLBCL patients presenting with risk factors at diagnosis 
(aged-adjusted international prognostic index (aaIPI) ≥1). 
Selected young patients with adverse prognostic factors plus insufficient response after induction treatment 
might benefit from a consolidation treatment
6–8
 such as autologous stem cell transplantation (ASCT). Interim-
PET analysis using a semiquantitative approach (so-called ΔSUVmax) might help to earlier identify patients for 
whom ASCT could improve disease control
9–12
. 
The aim of the GAINED trial is to compare obinutuzumab to rituximab when combined with an intensified 
chemotherapy regimen delivered every 14 days (ACVBP-14 or CHOP-14) followed by a PET-driven 




Study design and participants 
This open-label (NCT01659099), multicenter randomized phase 3 study was designed by the Lymphoma Study 
Association (LYSA) and conducted in 99 centers (Belgium and France). Eligible patients were 18 to 60 years old 
with newly diagnosed untreated histologically proven CD20+ DLBCL (2008 WHO classification), aaIPI≥1, at 
least one hypermetabolic lesion at baseline PET, eligibility for ASCT and had a life expectancy of ≥3 months. 
Patients not previously diagnosed with indolent lymphoma and presenting a DLBCL with small cell infiltration 
in bone marrow or lymph node at diagnosis were also eligible. Patients were required to have normal liver, renal 
and hematological functions unless abnormalities were related to DLBCL. Patients with altered cardiac function 
or uncontrolled diabetes mellitus interfering with normal application of protocol treatment were not eligible for 
inclusion. Patients presenting a central nervous system involvement at diagnosis were excluded. The study was 
approved by the French and Belgian Health authorities, the Ouest VI (Brest, France) ethics committee and by the 
institutional review boards in Belgium. It was performed in accordance with the Declaration of Helsinki and 
Guidelines for Good Clinical Practice, patients provided written informed consent.  
Procedures 
Patients were enrolled by center with the LYSARC e-Rando system and randomly assigned 1:1 to receive either 
rituximab or obinutuzumab. Randomization was done centrally with the permuted block method and stratified 
according to chemotherapy (CHOP vs ACVBP) and age-adapted international prognosis index (aaIPI: 1 vs 2-3). 
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Study design is shown in figure 1.  Treatment was divided in two phases, induction and consolidation. Induction 
consisted in 4 courses of CHOP or ACVBP delivered every 14 days. At its opening, each center was asked to 
choose either CHOP or ACVBP, and all patients included in the center were treated with the same chemotherapy 
regimen. All chemotherapy regimens are detailed in the full version of the protocol (supplemental data). In 
addition to CHOP or ACVBP, patients received obinutuzumab (O-CHOP or O-ACVBP) or rituximab (R-CHOP 
or R-ACVBP) according to randomization. Rituximab (375mg/m2) and obinutuzumab (1g flat dose) were 
infused at d1 of each cycle, except for cycle 1 where one infusion of obinutuzumab (1g flat dose) was given at 
d8. Prophylaxis for CNS involvement included 15mg of methotrexate IT at day 1 of the first four cycles.   
Responses during induction were assessed by PET. All eligible patients had a baseline PET scan 
(PET0). PET2 was scheduled 2 weeks after the second cycle and PET4 was scheduled 2 weeks after completion 
of induction chemotherapy (four cycles). Patients were scanned on the same camera for all PET scans. Whole-
body acquisition from groin to head was started within 60±10 min of injection of 5 MBq/kg 18F-FDG. 
Interpretations of PET2 and PET4 were based on the ΔSUVmax method. PET images were sent through a web 
platform and masked for independent central review by four expert reviewers (EI, ABR, FB, CBM). ΔSUVmax 
was calculated as: ΔSUVmax = 100´[(SUVmaxPET0 – SUVmaxPETX)/SUVmaxPET 0] as previously 
described 9–11. For PET2, the ΔSUVmax cut-off was 66% (PET2 considered as negative if ΔSUVmax>66% and 
positive if ≤66%)9. For PET4, the ΔSUVmax cut-off was 70% (PET4 considered as negative if SUVmax>70% 
and positive if ≤70%). The Deauvile 5-point scale, with grades 1,2,3 classified as negative and grades 4,5 
classified as positive, was used for patients whose PET0 SUVmax was <10, or interim with SUVmax>5 and 
ΔSUVmax>66% for PET2 or ΔSUVmax>70% for PET4. This was recommended by the 2011 Menton 
workshop13. The centrally reviewed PET results were then sent back to the investigators, together with the per-
protocol recommended consolidation treatment allocation for all patients.  
The consolidation phase was adapted to PET2 and 4 results. Patients in response after cycle 2 
(ΔSUVmax < 66%) and 4 (ΔSUVmax <70%) (PET2-/4-) received consolidation therapy. For patients treated 
with CHOP, this consisted of 4 courses of O- or R- CHOP. For patients treated by O- or R- ACVBP this 
consisted of 2 cycles of high-dose methotrexate (3g/m2) every 14 days followed by four cycles of ifosfamide 
(1.5g/m2 at D1) plus etoposide (300mg/m2 at D1) every 14 days, and two cycles of sub-cutaneous cytarabine 
(100mg/m2 for 4 days) delivered every 14 days for. Patients received obinutuzumab or rituximab according to 
initial randomization. Patients in response after cycle 4 but not after cycle 2 (PET2+/4) received two courses of 
high-dose methotrexate (3g/m2) every 14 days followed by autologous stem cell transplantation (ASCT). The 
conditioning regimen for ASCT was BEAM (details in supplemental data). Collection of peripheral blood stem 
cell progenitors was organized after induction cycle 3 or 4 for PET2+ patients. The target dose of collected 
CD34+ cells was 3x106 cells/kg.  Patients who did not reach response after cycle 4 and regardless response after 
cycle 2 (PET4+) were classified as non-responders and salvage therapy was considered at the discretion of the 
local investigator. 
In addition to PET, the following assessments were also mandatory: CT at diagnosis and after four cycles of 
chemotherapy, at the end of treatment, and every 6 months until the end of follow-up; bone-marrow (BM) 
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laboratory assessments at inclusion and before each cycle of chemotherapy. All diagnoses were performed by 
local pathologists and centrally reviewed by two LYSA-pathology experts. The Cell of origin (COO) of DLBCL 
was analyzed by Nanostring technology and according to the Hans algorithm. 
Trial treatments were stopped in the following cases: lymphoma progression, toxic effects from study 
treatment, concomitant illness or protocol violations that precluded continuation, start of a new treatment for 
lymphoma, consent withdrawal, or refusal to continue treatment  
Adverse events were assessed after each cycle of chemotherapy and graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, and treatment-related toxicities 
were reported by study group.  
Outcomes 
The primary endpoint was the 2-year event-free survival (EFS). EFS was defined as the time from randomization 
to PET positivity (according to ΔSUVmax criteria after cycle 2 or 4 based on central PET review), progression 
or relapse (according to Cheson 2007 criteria), modification of planned treatment non-related to progression 
(including radiotherapy), death of any cause. For patients who were not PET positive after cycle 2 or 4, or who 
had not progressed, relapsed, received a new anti-lymphoma treatment non-related to progression and were alive 
at the time of analysis, EFS was censored at the date of last disease assessment. The key secondary endpoints 
were safety, early metabolic response according to PET after cycles 2 and 4, overall response rate and best 
overall response rate after 4 cycles and end of treatment according to Cheson 2007 and 1999 criteria, duration of 
response (DOR), progression-free survival (PFS) and overall survival (OS).  
Statistical analysis  
We assessed the efficacy of obinutuzumab compared to rituximab in terms of EFS. We hypothesized superiority 
of the obinutuzumab arm as an 8% or higher improvement of 2-year EFS compared to the rituximab arm. This 
would correspond to a 2-year EFS greater than 73% in the obinutuzumab arm. Superiority would be established 
if the upper limit of the hazard ratio was lower than 0.73 with an alpha of 2.5% (one-sided test) and a power of 
80%. We used an exponential model to calculate sample size. Hypothesis calculation was based on an estimate 
of 65% 2-year EFS in the rituximab treatment group. We planned to enroll 670 patients, including an estimated 
10% drop out, to observe a total of 345 EFS events. Two interim analyses of the primary endpoint were planned 
(according to the Lan-DeMets sequential designed to test futility and superiority) after 33% and 66% of the 
scheduled events needed for the final analysis had been recorded. The first interim analysis was performed in 
2015 (data cutoff date April 14, 2014): the unilateral logrank p value (p=0.0573) for stratified EFS was inferior 
to the preplanned futility bound (p=0.5856) and superior to the preplanned superiority bound (p=0.0001). This 
led the data and safety monitoring committee to recommend continuation of the study. The second interim 
analysis was performed in 2017 (data cutoff date August 1, 2016): the unilateral logrank p value (p=0.1321) for 
stratified EFS was superior to the preplanned futility bound (p=0.069) leading the data and safety monitoring 
committee to recommend stopping the study for futility. As all the patients were enrolled at the time of the 
second interim analysis with only 25.2 months of median follow-up, the data and safety monitoring committee 
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The data cutoff for the present analyses was December 1, 2017. The EFS, progression-free survival 
(PFS), OS and duration of response (DOR) analyses were done with an intention-to-treat (ITT) method, thus 
including all patients randomly assigned to a treatment group. Prespecified sensitivity analyses such as 
unstratified analyses, analysis based on efficacy set (ES) and analysis based on per protocol set (PP), were 
performed for the primary endpoint. The efficacy set (ES) included all patients randomized who received at least 
one dose of monoclonal antibody and had PET2 and PET4 (unless there was previous disease progression). The 
per protocol set (PP) excluded patients with major protocol deviations. Safety was assessed in patients who 
received at least one dose of study treatment (obinutuzumab or rituximab).  
Survival estimates with 95%CIs were calculated with the Kaplan-Meier method. The survival 
distributions were compared with the log-rank test, and Cox proportional hazard regression models were used to 
estimate HRs and associated 95%CIs.  
To compare the relative effect of the full PET-driven strategy on progression-free (PFS) and overall 
survival (OS) according to baseline characteristics found to influence outcomes in univariate analysis, a Cox 
proportional hazard regression model was fitted, including PET profile and aaIPI as explanatory variables.  
Response and PET2 and PET4 results were expressed with 95% exact Clopper Pearson CI limits and compared 
with the χ² test. Differences between groups were significant if p values were less than 0.025 (one-sided) for 
EFS and less than 0.05 (two-sided) for PFS and OS. 
Funding source  
Roche pharma provided obinutuzumab and funded the trial. The funder had no role in trial design, data 
collection, data analysis, data interpretation, or writing of the report. Corresponding authors had full access to all 
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RESULTS 
From September 20, 2012, to July 30, 2015, 670 patients (ITT set) were enrolled and randomly assigned to 
receive either standard treatment with rituximab (n=334) or obinutuzumab (n=336). Patients’ characteristics at 
baseline (table 1) were well balanced across the two treatment groups (and according to chemotherapy, see 
appendix), except for gender (p=0.016). The median age at baseline was 48 years (18–61). Median time from 
diagnosis to treatment was 20 days (2-149). Six hundred and forty-six (96.4%) out of 670 patients underwent a 
centrally assessed pathology biopsy, among whom 580 (86.6%) had a confirmed CD20+ DLBCL.  
Among the 670 enrolled patients, 339 patients received at least one cycle of CHOP (with obinutuzumab 
in 169 cases and rituximab in 170 cases) and 324 received at least one cycle of ACVBP (with obinutuzumab in 
163 cases and rituximab in 161 cases) (table 1). Three hundred and twelve patients out of 336 (93%) and out of 
334 (93%) completed induction treatment in the obinutuzumab and rituximab arms, respectively (figure 2). 
Reasons for treatment discontinuation during induction were mainly treatment-related toxicity (n=16; 2.4%). 
After completion of induction, main reasons for treatment discontinuation in PET4 negative patients were 
treatment-related toxicity in 31 patients (6.4%), major protocol violation in 10 patients (2.0%) and patient 
decision in 14 cases (2.9%). 
PET2 and 4 were performed in 302 (90%) and 297 (88%) in the obinutuzumab arm and 302 (90%) and 
289 (86.5%) patients in the rituximab arm. PET2 and PET4 positivity rates were slightly higher in the rituximab 
arm compared to the obinutuzumab arm but did not reach statistical significance (table 2). As shown in figure 2, 
401 (69%) were PET2-/4- of whom 398 (99.3%) received the planned immunochemotherapy. Eighty seven 
(15%) patients were PET2+/PET4- of whom 74 (85%) received the planned consolidation therapy followed by 
ASCT. Ninety three patients (16%) had positive PET4 of whom 91 (97.8%) received salvage therapy. In all, 227 
patients (68%) completed the planned treatment in the obinutuzumab arm (including 124 patients (73%) with 
CHOP and 103 (63%) with ACVBP) and 197 (59%) in the Rituximab arm (including 109 patients (64%) with 
CHOP and 88 (55%) with ACVBP (figure 2)). 
The median follow-up after randomization was 38.7 months (95%CI 36.9-40.0). For the primary 
efficacy analysis (ITT set), 147 (43.8%) in the obinutuzumab arm and 155 (46.4%) in the rituximab arm had an 
event. Most frequent events were PET 2 or 4 positivity (85 patients (25%) in the obinutuzumab arm and 107 
patients (32%) in the rituximab arm) (see appendix). The 2-year EFS estimates were 59.8% (95%CI 54.3-64.8) 
in the obinutuzumab arm and 56.6% (95%CI 51.1-61.8) in the rituximab arm (stratified logrank: p=0.123; 
unstratified Logrank: p=0.127; HR=0.88, 95%CI 0.7-1.1) (figure 3a) and did not differ according to both 
chemotherapy and aaIPI in both arms (table 3). The efficacy of obinutuzumab and rituximab in terms of EFS 
was consistent across prespecified subgroups except for patients of 50 years old or younger (HR=0.71, 95%CI 
0.5-0.9), and for those with at least 40% of tumor cells expressing MYC (HR=0.55, 95% CI 0.4-0.8) (figure 4a). 
EFS in the efficacy set (n=617) did not differ significantly between the two arms (stratified logrank: p=0.077, 
unstratified logrank: p=0.074; HR=0.84, 95%CI 0.7-1.1; figure 3b). In the PP set, results were similar (stratified 
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Response rates after 4 cycles of induction and at the end of treatment (according to Cheson 1999 and 
2007 (see appendix)) were similar in both arms. Duration of response (Cheson 2007 criteria) did not differ 
significantly between the two arms (2 and 4-year DOR: 87.4% (95%CI 83.1-90.7) and 82.8% (95%CI 77.4-87.0) 
vs 86.8% (95%CI 82.3–90.2) and 83.4% (95%CI 78.2-87.4), HR=0.98 (95%CI 0.7-1.5), p=0.94) (see appendix). 
PFS did also not differ significantly between the two arms (p=0.87; HR=1.03, 95%CI 0.7-1.4). The 2 and 4-year 
PFS estimates in the ITT population were respectively 83.2% (95%CI: 78.7-86.8) and 77.5% (95% CI: 72.2-
81.9) in the obinutuzumab arm and 83% (95%CI 78.5-86.7) and 78.8% (95%CI 73.8-83) in the rituximab arm 
(figure 5). Results were similar in the ES (p=0.92) and PP sets (p=0.96). The efficacy of obinutuzumab and 
rituximab in terms of PFS was similar across prespecified subgroups (figure 4b). OS was similar between both 
arms (p=0.85; HR=0.96, 95%CI 0.6-1.5). The 2 and 4-year OS were respectively 90.7% (95%CI 87.0-93.4) and 
88.2% (95%CI 83.9-91.4) in the obinutuzumab arm vs 91.8% (95%CI 88.1-94.3) and 86% (95%CI 80.8-89.8) in 
the rituximab arm (figure 5). 70 out of 663 patients (safety set) (10.6%) died of whom 34 (10.2%) were in the 
obinutuzumab arm and 36 (10.9%) were in the rituximab arm. Main causes of death were lymphoma in 45 
patients (6.8%) (19 in the obinutuzumab and 26 in the rituximab arms) and toxicity of the study treatment in 9 
patients. 
A univariate analysis showed that Ann Arbor Stage III-IV, ECOG status >1, aaIPI>1, tumor bulk 
≥10cm, Bcl2 expression in ≥70% of tumor cells, were associated with lower PFS (table 4). On the other hand, 
LDH level, COO according to the Hans algorithm or gene expression profile, MYC expression, and double 
expression of BCL2 and MYC had no effect on PFS. Ann Arbor Stage III-IV, ECOG status >1, aaIPI>1 were 
also associated with a worse OS. By contrast, LDH level, tumor bulk, COO that had no significant effect. A 
positive PET2 was not associated to an inferior outcome when PET4 was negative. PET2-/PET4- patients 
assigned to immunochemotherapy and PET2+/PET4- patients allocated to ASCT had similar PFS (2 and 4-year 
PFS: 89.9% (95%CI 86.5–92.5) and 83% (95%CI 78.5–86.7) vs 83.9% (95%CI 74.3–90.1) and 83.9% (95%CI 
74.3–90.1)) and OS (2 and 4-year OS: 94.8% (95%CI 92.1–96.6) and 90.3% (95%CI 86.2–93.2) vs 92.8% 
(95%CI 84.7–96.7) and 90.2% (95%CI 81.4–95)). Conversely, PET4 positivity was associated with an increased 
risk of relapse, progression or death, regardless of the treatment group (2 and 4-year PFS: 62% (95%CI 51.3-71) 
and 60.9% (95%CI 50.1–70), HR=3.44, 95%CI 2.3–5.1; p<0.001; 2 and 4-year OS: 83.1% (95%CI 73–89.7) and 
81.5% (95%CI 71.1–88.5), HR=2.49, 95%CI 1.4–4.5; p=0.005) (figure 6). In a multivariable analysis PET4 
positivity was the only parameter that remained statistically significant for both PFS and OS (p<0.001) while 
patients with IPI 2-3 (p=0.001) and percentage of Bcl-2 positive cells ≥70% (p=0.047) presented a worse OS but 
not PFS. Ann Arbor stage III-IV (p<0.001) and bulky disease (p=0.039) were statistically significant for PFS but 
not for OS (table 4). 
During induction phase, the most common grade 3-4 adverse events in the safety set were 
hematological as nearly half of the patients experienced neutropenia in both arms. Grade 3-5 infections were 
more frequent in the obinutuzumab arm (21%) compared to the Rituximab arm (12%). Other AEs were standard 
for intensive chemotherapy (See appendix table 7). The cumulative incidence of second primary malignancies 
was 4.1% in 27 patients and similar between the two groups (15 (4.5%) in 332 patients of the obinutuzumab arm 
and 12 (3.6%) in 331 patients of the Rituximab arm) while more acute leukemia or myelodysplasia syndrome 
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DISCUSSION 
 
The GAINED trial demonstrates that obinutuzumab does not provide better EFS than rituximab in combination 
with chemotherapy delivered every 14 days for treatment-naïve young patients with IPI≥1 DLBCL. PFS and OS 
are similar in both arms. Analysis of subgroups does not show a subset of patients who may benefit from 
obinutuzumab rather than rituximab.  
The GALLIUM
14
 study demonstrated that, in newly diagnosed follicular lymphoma patients, 
obinutuzumab plus chemotherapy followed by an obinutuzumab maintenance significantly improves PFS 
compared to the same treatment with rituximab. In contrast, the GOYA trial
15
 fails to show superiority of 
obinutuzumab over rituximab in treatment-naïve DLBCL patients >18yrs. The two antibodies, in combination 
with CHOP, show similar 3-year PFS (median follow-up of 29 months): 70% in the obinutuzumab arm versus 
67% in the rituximab arm. The present trial addresses the same question as the GOYA trial but it looks at a 
different population and uses a different consolidation treatment strategy based on interim PET results. Indeed, 
patients enrolled in GAINED are all <60yrs and transplant-eligible at diagnosis while in GOYA the median age 
was 62 years with more than half of the patients IPI low/intermediate. The GOYA trial compared 8 rituximab vs 
10 obinutuzumab infusions associated to CHOP21 while GAINED compares rituximab vs obinutuzumab in 
young patients with advanced disease who had double negative interim PET (69%). These last patients are those 
who received complete planned antibodies infusions. The GAINED and GOYA trials use different endpoints, 
EFS and PFS respectively. The PET-driven design of the GAINED trial led to the choice of EFS, with PET 
positivity results after 2 and 4 courses considered as events. Despite all these discrepancies, both trials reach the 
same conclusion that obinutuzumab and rituximab are equivalent in the treatment of DLBCL regardless of age, 
IPI score, COO, treatment intensity and use of PET-driven strategy.  
The GAINED study provides interesting additional findings. The 2 and 4-year PFS in the whole cohort 
are 83.1% (95%CI 80–85.8) and 78.1% (95%CI 74.6–81.2) respectively. These results are the best published so 
far in young patients with aaIPI≥16,8,16,17. The PET-driven strategy could help explain these good outcomes. 
Indeed, Interim PET identifies the DLBCL patients less sensitive to chemotherapy, those at high risk of early 
relapse or progression6,12. A post Hoc analysis of the LNH07-3B study shows that SUVmax improves the 
prognosis value of interim PET after cycles 2 and 4 compared to visual analysis6,11. In the present study, 
SUVmax is used prospectively in order to interpret interim PET and to discriminate patients with different 
outcomes. The PETAL study which uses the ΔSUVmax method with the same 66% cut-off after 2 cycles of 
immunochemotherapy 9,11,18, demonstrates that DLBCL patients have significantly better outcomes when 
SUVMax>66%17. It is interesting to compare the efficacy of the consolidation strategy applied to PET2+ 
patients in the PETAL and GAINED trials. In the present trial, PET2+/PET4- patients (15%) were allocated to 
ASCT while in PETAL PET2+ patients were randomized between continuing treatment with R-CHOP and a 
Burkitt-like regimen. PETAL demonstrates that the Burkitt-like experimental chemotherapy is not superior to R-
CHOP and confirms that PET2 positivity is an independent prognostic marker. In view of this, PET2+/PET4- 
patients underwent ASCT and their outcomes are identical to PET2-/PET4- patients. This suggests that ASCT 
may overcome the bad prognostic value of PET2 positivity in the subset of patients achieving a good response 
after 4 cycles of induction, but the lack of randomization regarding treatment consolidation for PET2+/PET4- 
patients does not allow formal conclusion in favor of ASCT consolidation versus a non-transplant therapy. Our 
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groups with PET4 positive patients being those with the poorer outcome, despite salvage treatment. These last 
patients require new therapy options and should be candidate for innovative strategies. CAR T-cells have been 
recently approved for relapse refractory DLBCL and could be an interesting option for PET4+ patients who can 
be identified earlier, thanks to PET2 response assessment using SUVmax. In contrast, PET2-/PET4- high aaIPI 
score patients (nearly 70% of patients) experience prolonged response duration (4-year PFS=83.1% and 
OS=90.2%). This raises the question of therapeutic reduction. Indeed, low risk IPI PET2 negative young 
DLBCL patients could be cured with only 4 cycles of chemotherapy instead of 6 cycles of R-CHOP19 . 
 CHOP remains the most widely used regimen in DLBCL and the reference polychemotherapy in 
clinical trials. Other more intensive polychemotherapy regimen are used in daily practice, such as DA-EPOCH 
or ACVBP. ACVBP demonstrated superiority over CHOP in aaIPI=1 patients
5
. In the GAINED study, patients 
treated with ACVBP have a lower rate of PET2 positivity which, thanks to the PET-driven strategy, diminishes 
the number of patients referred to autograft and/or salvage therapy. Toxicity of ACVBP regimen is superior to 
CHOP and the present study shows that ACVBP enhances neither PFS nor OS compared to R-CHOP (including 
for patients with aaIPI=1). Recent phase III studies added new molecules (bortezomib/ibrutinib/lenalidomide) in 
combination with R-CHOP, but none demonstrated superiority over R-CHOP
20–22
. This highlights the need to 
better decipher the DLBCL molecular heterogeneity background in order to set up new personalized biology-
driven therapies. PET-driven strategy is among those new tools which could help tailor personalized approaches 
in future trials. Indeed, baseline total metabolic volume
23–25
 and interim-PET results added to longitudinal 
analysis of ctDNA
26,27
 could provide an interesting multi-parameters approach capable of refining the prediction 
of early response to treatment. 
In conclusion, obinutuzumab does not provide outcome benefits compared to rituximab in the first-line 
treatment of young DLBCL patients with advanced disease. A PET-driven approach based on SUVmax criteria 
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FIGURES AND TABLES LEGENDS 
 
Table 1 : Patients’ characteristics at baseline.  ITT, intention-to-treat ;  ECOG , Eastern Cooperative 
Oncology Group scale ;  LDH, lactate deshydrogenase ;  aaIPI, age-ajusted International prognostic index ;  
DLBCL, diffuse large B-cell lymphoma ; COO, cell of origin;  GCB, germnial-center B-cell ;  ABC,  activated  
B-cell ;  DE, double expressor ; CHOP, cyclophosphamide (750mg/m² at D1), doxorubicine (50mg/m² at D1), 
vincristine (1.4mg/m², max 2mg, at D1) and prednisone (40mg/m² D1-D5) ; ACVBP included doxorubicine 
(75mg/m2 at D1), prednisone (60mg/m2 D1-D5), cyclophosphamide (1200mg/m2 at D1), vindesine (2mg/m2 at 
D1 and 5) and bleomycine (10mg at D1 and 5). 
 
 
Table 2: interim-PET results according to the central review in the ITT population. CHOP, 
cyclophosphamide (750mg/m² at D1), doxorubicine (50mg/m² at D1), vincristine (1.4mg/m², max 2mg, at D1) 
and prednisone (40mg/m² D1-D5) ; ACVBP included doxorubicine (75mg/m2 at D1), prednisone (60mg/m2 D1-
D5), cyclophosphamide (1200mg/m2 at D1), vindesine (2mg/m2 at D1 and 5) and bleomycine (10mg at D1 and 
5). 
 
Table 3: 2y-EFS according to treatment arm in the ITT population. EFS, event-free survival; ITT , intention 
-to-treat;  CHOP, cyclophosphamide (750mg/m² at D1), doxorubicine (50mg/m² at D1), vincristine (1.4mg/m², 
max 2mg, at D1) and prednisone (40mg/m² D1-D5) ; ACVBP included doxorubicine (75mg/m2 at D1), 
prednisone (60mg/m2 D1-D5), cyclophosphamide (1200mg/m2 at D1), vindesine (2mg/m2 at D1 and 5) and 
bleomycine (10mg at D1 and 5). 
 
Table 4:  Factors influencing patient’s outcome.  aaIPI, age-ajusted International prognostic index ; ECOG , 
Eastern Cooperative Oncology Group scale ;  LDH, lactate deshydrogenase ; CHOP, cyclophosphamide 
(750mg/m² at D1), doxorubicine (50mg/m² at D1), vincristine (1.4mg/m², max 2mg, at D1) and prednisone 
(40mg/m² D1-D5) ; ACVBP included doxorubicine (75mg/m2 at D1), prednisone (60mg/m2 D1-D5), 
cyclophosphamide (1200mg/m2 at D1), vindesine (2mg/m2 at D1 and 5) and bleomycine (10mg at D1 and 5) ; 
HR, hazard ratio  
 
Figure 1: Study design. DLBCL, diffuse large B-cell lymphoma, C, cycle ;  aaIPI, age-ajusted International 
prognostic index ; MTX, methotrexate ;  CHOP, cyclophosphamide (750mg/m² at D1), doxorubicine (50mg/m² 
at D1), vincristine (1.4mg/m², max 2mg, at D1) and prednisone (40mg/m² D1-D5) ; ACVBP included 
doxorubicine (75mg/m2 at D1), prednisone (60mg/m2 D1-D5), cyclophosphamide (1200mg/m2 at D1), vindesine 
(2mg/m2 at D1 and 5) and bleomycine (10mg at D1 and 5) ; ASCT autologous stem-cell transplantation ;    
BEAM, carmustine 300mg/m2 at D-6; etoposide 200mg/m2 from D-6 to -3; cytarabine 200mg/m2/12H from D-
6 to -3; melphalan 140mg/m2 at D-2 
 
Figure 2: Flow chart 
 
Figure 3: EFS in ITT (a), ES (b), and PP (c) populations. EFS, event-free-survival;  ITT, intention-to-treat; 
ES, efficacity set; PP, per protocol 
Figure 4: Unstratified Hazard ratio for EFS (panel A) and PFS (panel B) in predefined subsets of patients. 
EFS, event-free survival; PFS, progression-free survival;  ECOG , Eastern Cooperative Oncology Group scale ;  
LDH, lactate deshydrogenase ;  aaIPI, age-ajusted International prognostic index ;  DLBCL, diffuse large B-cell 
lymphoma ;  GCB, germnial-center B-cell ;  ABC,  activated  B-cell ;  DE, double expressor ;  CHOP, 
cyclophosphamide (750mg/m² at D1), doxorubicine (50mg/m² at D1), vincristine (1.4mg/m², max 2mg, at D1) 
and prednisone (40mg/m² D1-D5) ; ACVBP included doxorubicine (75mg/m2 at D1), prednisone (60mg/m2 D1-
D5), cyclophosphamide (1200mg/m2 at D1), vindesine (2mg/m2 at D1 and 5) and bleomycine (10mg at D1 and 
5). 
 
Figure 5: Unstratified PFS (A) and OS (B) according to randomization arms and PFS according to PET2 
PET4 responses in the whole cohort (C) and OS according to iPET response (D). PFS, progression-free 
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Table 1 : Patients’ characteristics at baseline 
 ITT  
(n=670) 
Efficacy set  
(n=617) 




(n = 336) 
Rituximab 
(n = 334) 
Obinutuzumab 
(n = 311) 
Rituximab 
(n = 306) 
Obinutuzumab 
(n = 296) 
Rituximab 
(n = 298) 
Median age (range), 
years 
49 (19-60) 48 (18-61) 49 (19-60) 47 (18-60) 49 (19-60) 47 (18-60) 






















Missing 0 1 1 1 0 1 



























































273 (81.3%) 271 (81.1%) 255 (82.0%) 238 (77.8%) 243 (82.1%) 233 (78.2%) 






































































































BCL2 expression(n=544)       
≥70% 186 (69.4%) 208 (75.4%) 174 (68.8%) 188 (74.3%) 167 (68.4%) 186 (74.7%) 
<70% 82 (30.6%) 68 (24.6%) 79 (31.2%) 65 (25.7%) 77 (31.6%) 63 (25.3%) 
No or insufficient 
material  
70 62 60 55 54 51 
MYC expression(n=466)       
≥40% 120 (51.7%) 123 (52.6%) 115 (51.6%) 109 (51.2%) 114 (52.8%) 106 (51.0%) 
<40% 













DE MYC/BCL2 (n=454)       
Yes  93 (40.6%) 92 (40.9%) 88 (40.0%) 80 (39.0%) 87 (40.8%) 80 (39.8%) 
No 136 (59.4%) 133 (59.1%) 132 (60.0%) 125 (61.0%) 126 (59.2%) 121 (60.2%) 





























† Follicular lymphoma (FL) grade 3B (n=7), FL grade 3A (n=6), FL grade 1-2 (n=7), Follicular lymphoma of undetermined 
grade (n=2), Nodular lymphocyte predominant Hodgkin lymphoma (n=4), Mantle cell lymphoma – pleomorphic variant 
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lymphoma (n=1), Burkitt lymphoma / leukaemia (n=1) , Precursor B lymphoblastic leukaemia / lymphoma (n=1), anaplastic 
large cell lymphoma- ALK + (n=1). # DLBCL include DLBCL NOS, PMBL, EBV DLBCL, High grade B-cell lymphoma 
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  Obinutuzumab Rituximab  
 N 2y-EFS (%) 95%CI  N 2y-EFS (%)  95%CI 
Unstratified EFS  336 59.8 54.3-64.8 334  56.6 51.1-61.8 
Stratified EFS          
aaIPI1 
CHOP 74 62.2 50.1-72.1 73 58.8 46.7-69.1 
ACVBP 76 60.3 48.4-70.3 74 61.9 49.8-71.9 
aaIPI2-3 
CHOP 97 56.7 46.2-65.8 99 51.9 41.6-61.3 
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Table 4:  Factors influencing patient’s outcome 
 
     
PFS   OS 
     Univariate analysis  Multivariable analysis   Univariate analysis  Multivariable analysis 
Risk factors n (%) 2y-PFS 








p  2y-OS 
 % (95%CI) 
HR 
(95%CI) 
p  HR 
(95%CI) 
p 
Age >50 y 272 (41%) 82 (76.8-86.1)  1.17 (0.8 – 1.6) 0.36     89.9 (85.5-93.0) 1.42 (0.9-2.2) 0.13    
 ≤50 y 398 (59%) 83.9 (79.9-87.1)        92.1 (89.0-94.4)      
Gender Male 373 (56%) 82.4 (78.1-85.9) 
 
1.17 (0.8 – 1.6) 0.36 
   
 91.9 (88.5-94.3) 0.96 (0.6-1.5) 0.88     
Female 297 (44%) 84 (79.3-87.7) 
      
 90.5 (86.4-93.4)      
ECOG ≥ 2 94 (14%) 74.1 (63.9-81.8) 
 
1.68 (1.1-2.5) 0.021 
   
 84.1 (74.6-90.3) 2.22 (1.3-3.7) 0.005     
0-1 575 (86%) 84.5 (81.3-87.3) 
      
 92.4 (89.8-94.3)      
Ann Arbor stage III-IV 552 (82%) 80.6 (77.0-83.7) 
 
3.78 (1.8-7.7) <0.001 
 
3.71 (1.7-8.0) <0.001  89.5 (86.6-91.9) 8.62 (2.1-35.3) <0.001     
I-II 118 (18%) 94.9 (89.0-97.7) 
      
 99.1 (94.0-99.9)      
LDH Elevated 487 (73%) 83.6 (80-86.6) 
 
0.94 (0.6-1.4) 0.73 
   
 91.0 (88.0-93.2) 1.16 (0.7-2.0) 0.57     
Normal 183 (27%) 81.7 (75.3-86.6) 
      
 92.1 (86.9-95.2)      
aa-IPI 2-3 383 (58%) 80.8 (76.4-84.4) 
 
1.46 (1.0-2.1) 0.034 
   
 88.8 (85.0-91.6) 2.07 (1.2-3.5) 0.003  3.91 (1.7-8.8) 0.001  
0-1 282 (42%) 86 (81.3-89.6) 
      
 94.5 (91.0-96.6)      
Bulk ≥10cm 213 (32%) 78.3 (72.1-83.3) 
 
1.42 (1.0-2.0) 0.05 
 
1.49 (1.0-2.2) 0.039  89.2 (84.0-92.7) 1.45 (0.9-2.3) 0.12     
<10cm 457 (68%) 85.4 (81.7-88.3) 
      
 92.2 (89.3-94.4)      
Hans Score non GC 250 (47%) 81.9 (76.6-86.2) 
 
1.15 (0.8-1.7) 0.46 
   
 89.6 (85.0-92.9) 1.39 (0.8-2.3) 0.20     
GC 282 (53%) 83.9 (79-87.7) 
      
 93.0 (89.3-95.5)      
BCL2 ≥70% 391 (73%) 80.6 (76.3-84.2) 
 
1.99 (1.2-3.3) 0.004 
   
 90.6 (87.2-93.2) 1.84 (0.9-3.6) 0.064  2.41 (1.0-5.7) 0.047  
<70% 148 (27%) 89.7 (83.5-93.7) 
      
 94.3 (89.0-97.1)      
MYC ≥40% 241 (52%) 81.3 (75.8-85.7) 
 
1.39 (0.9-2.1) 0.12 
   
 89.8 (85.1-93.0) 1.31 (0.7-2.3) 0.34     
<40% 221 (48%) 86.2 (80.8-90.1) 
      
 92.9 (88.5-95.7)      
DE Myc/Bcl2 yes 183 (41%) 79.8 (73.2-84.9) 
 
1.46 (0.96-2.2) 0.075 
   
 88.7 (83.1-92.6) 1.41 (0.8-2.5) 0.23     
no 267 (59%) 85.9 (81.1-89.6) 
      
 92.6 (88.6-95.2)      
Treatment arm Obinutuzumab 336 (50%) 83.2 (78.7-86.8) 
 
1.03 (0.7-1.4) 0.87 
 
0.95 (0.7-1.4) 0.77  90.7 (87.0-93.4) 0.96 (0.6-1.5) 0.86  0.89 (0.5-1.6) 0.69  
Rituximab 334 (50%) 83 (78.5-86.7) 
      
 91.8 (88.1-94.3)      
Chemotherapy CHOP 339 (51%) 82.7 (78.2-86.4) 
 
1.14 (0.8-1.6) 0.46 
 
1.06 (0.7-1.5) 0.76  92.0 (88.4-94.5) 1.10 (0.7-1.8) 0.70  0.85 (0.5-1.5) 0.59  
ACVBP 324 (49%) 84.7 (80.3-88.2) 
      
 91.6 (87.9-94.2)      
PET2/PET4 PET4+ 93 (16%) 62 (51.3-71.0)  3.44 (2.3-5.1) <0.001  3.17 (2.1-4.7) <0.001  83.1 (73.0-89.7) 2.49 (1.4-4.5) 0.005  3.61 (1.9-6.8) <0.001 
 PET2- or PET+/PET4- 493 (84%) 89 (85.8-91.4)        94.5 (92.1-96.3)      
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Not treated (n=3) ‡




- Concurrent illness (n=1)
- Major protocol violation (n=5)













































- Concurrent illness (n=1)






Reason of treatment discontinuation:
- PET 2-/4- (n=28)
o Toxicity (n=15)
o Major protocol violation (n=3)
o Progression (n=1)
o Consent withdrawal (n=1)
o Other (n=8)
- PET 2+/4- (n=8)
o Toxicity (n=1)
o Major protocol violation (n=3)
o Progression (n=1)
o Other (n=3)
Reason of treatment discontinuation:
- PET 2-/4- (n=23)
o Toxicity (n=14)
o Major protocol violation (n=2)
o Concurrent illness (n=1)
o Insufficient response (n=1)
o Other (n=5)
- PET 2+/4- (n=5)
o Toxicity (n=1)
o Major protocol violation (n=2)
o Insufficient response (n=1)






† Major protocol violation (Cerebral lymphoma) (n=1), Concurrent illness (Septic thrombophlebitis due to Staphilococcus aureus) (n=1), Evolution of Lymphoma before treatment (n=1), Misdiagnosis (Acute Leukaemia) (n=1) 
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Figure 4: Unstratified Hazard ratio for EFS (panel A) and PFS (panel B) in predefined subsets of patients 
 
A              B 
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Figure 5 : Unstratified PFS according to randomization arms (A); unstratified OS  according to randomization arm (B); PFS according to PET2 




A       B      C 













87 85 83 80 76 62 48 33 16 5 0
401 399 391 374 357 302 210 127 68 21 0
93 89 79 67 59 42 31 21 10 3 0




























OS according to PET strategy - ITT
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